(OMCL) Omnicell - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US68213N1090
OMCL: Medication Management, Automation Solutions, Dispensing Systems, Pharmacy Automation, Inventory Management, Patient Engagement, Clinical
Omnicell, Inc. (NASDAQ:OMCL) is a global leader in medication management and healthcare technology, offering a comprehensive suite of solutions designed to optimize clinical workflows, improve patient safety, and enhance operational efficiency. The company provides automation, data analytics, and professional services to healthcare systems, pharmacies, and post-acute care facilities worldwide. Its product portfolio includes the XT Series automated dispensing systems, which streamline medication and supply management in nursing units and clinical areas. Omnicell also offers specialized dispensing systems tailored for hospitals, health systems, and post-acute care settings. Additionally, the company provides central pharmacy dispensing services, IV compounding solutions, and turnkey specialty pharmacy programs that assist health systems in establishing and managing entity-owned specialty pharmacies, including payer contracting, staffing, and 340B program administration.
Omnicell’s inventory optimization services leverage predictive and prescriptive analytics, benchmarking tools, and clinical resources to provide medication inventory visibility and improve decision-making. The company also offers patient engagement and clinical solutions, as well as financial tools to enhance care coordination and operational outcomes. Its medication adherence solutions include single-dose automation, automated filling equipment, and blister card packaging supplies. Software solutions guide users through manual filling processes, ensuring accuracy and efficiency. Omnicell further supports its clients with professional services such as technology installation, program management, customer education, and change management. Technical services include post-installation support, maintenance, and access to software upgrades. The company also operates in international markets, providing retail pharmacy and hospital automation solutions outside the U.S.
Omnicell, Inc. was founded in 1992 and was formerly known as Omnicell Technologies, Inc. before changing its name in 2001. Headquartered in Fort Worth, Texas, the company has established itself as a key player in the healthcare technology sector, focusing on innovative solutions to address the challenges of medication management and patient care. Web URL: https://www.omnicell.com
Additional Sources for OMCL Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
OMCL Stock Overview
Market Cap in USD | 1,470m |
Sector | Healthcare |
Industry | Health Information Services |
GiC Sub-Industry | Health Care Technology |
IPO / Inception | 2001-08-07 |
OMCL Stock Ratings
Growth Rating | -47.1 |
Fundamental | 19.2 |
Dividend Rating | 0.0 |
Rel. Strength | 4.4 |
Analysts | 3.78/5 |
Fair Price Momentum | 26.24 USD |
Fair Price DCF | 63.85 USD |
OMCL Dividends
No Dividends PaidOMCL Growth Ratios
Growth Correlation 3m | -93.3% |
Growth Correlation 12m | 27.7% |
Growth Correlation 5y | -75.8% |
CAGR 5y | -15.31% |
CAGR/Max DD 5y | -0.18 |
Sharpe Ratio 12m | -1.44 |
Alpha | 2.85 |
Beta | -0.070 |
Volatility | 43.59% |
Current Volume | 567.5k |
Average Volume 20d | 575.5k |
As of May 05, 2025, the stock is trading at USD 31.16 with a total of 567,516 shares traded.
Over the past week, the price has changed by +1.04%, over one month by -4.68%, over three months by -28.94% and over the past year by +3.94%.
Neither. Based on ValueRay Fundamental Analyses, Omnicell is currently (May 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 19.17 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of OMCL as of May 2025 is 26.24. This means that OMCL is currently overvalued and has a potential downside of -15.79%.
Omnicell has received a consensus analysts rating of 3.78. Therefor, it is recommend to hold OMCL.
- Strong Buy: 3
- Buy: 1
- Hold: 5
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, OMCL Omnicell will be worth about 28.3 in May 2026. The stock is currently trading at 31.16. This means that the stock has a potential downside of -9.05%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 50.7 | 62.7% |
Analysts Target Price | 50.7 | 62.7% |
ValueRay Target Price | 28.3 | -9.1% |